Role of Caspase-10-P13tBID axis in erythropoiesis regulation.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
08
02
2022
accepted:
12
09
2022
revised:
09
09
2022
pubmed:
7
10
2022
medline:
1
2
2023
entrez:
6
10
2022
Statut:
ppublish
Résumé
Red blood cell production is negatively controlled by the rate of apoptosis at the stage of CFU-E/pro-erythroblast differentiation, depending on the balance between erythropoietin (EPO) levels and activation of the Fas/FasL pathway. At this stage, activation of transient caspases through depolarization via mitochondrial outer membrane permeabilization (MOMP) is also required for terminal erythroid differentiation. Molecular mechanisms regulating the differential levels of MOMP during differentiation and apoptosis, however, remain poorly understood. Here we show a novel and essential role for the caspase-10-P13-tBID axis in erythroid terminal differentiation. Caspase-10 (but not caspase-8, which is activated during apoptosis) is activated at the early stages of erythroid terminal differentiation leading to the cleavage of P22-BID into P18-tBID, and later into P13-tBID. Erythropoietin (EPO) by inducing casein kinase I alpha (CKIα) expression, which in turn phosphorylates P18-tBID, prevents the generation of MYR-P15-tBID (leading to apoptosis) and allows the generation of P13-tBID by caspase-10. Unlike P15-tBID, P13-tBID is not myristoylated and as such, does not irreversibly anchor the mitochondrial membrane resulting in a transient MOMP. Likewise, transduction of a P13-tBID fragment induces rapid and strong erythroid terminal differentiation. Thus, EPO modulates the pattern of BID cleavage to control the level of MOMP and determines the fate of erythroblasts between apoptosis and differentiation. This pathway is impaired in 5q- myelodysplastic syndromes because of CK1α haplo-insufficiency and may contribute to erythroid differentiation arrest and high sensitivity of this disease to lenalidomide (LEN).
Identifiants
pubmed: 36202990
doi: 10.1038/s41418-022-01066-0
pii: 10.1038/s41418-022-01066-0
pmc: PMC9883265
doi:
Substances chimiques
Caspase 10
EC 3.4.22.-
Caspases
EC 3.4.22.-
Apoptosis Regulatory Proteins
0
Erythropoietin
11096-26-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-220Informations de copyright
© 2022. The Author(s).
Références
Nat Commun. 2015 Jul 29;6:7901
pubmed: 26219591
Cell Death Differ. 2017 Aug;24(8):1411-1421
pubmed: 28644437
Cell. 2003 Oct 3;115(1):61-70
pubmed: 14532003
FEBS Lett. 2009 Feb 18;583(4):848-54
pubmed: 19244619
Exp Cell Res. 1999 Nov 25;253(1):143-56
pubmed: 10579919
Cell Stem Cell. 2014 Aug 7;15(2):169-84
pubmed: 24953180
Nat Cell Biol. 2012 Mar 25;14(5):535-41
pubmed: 22446738
Cell Rep. 2017 Apr 25;19(4):785-797
pubmed: 28445729
Nature. 2014 Oct 9;514(7521):242-6
pubmed: 25156257
Cell Death Differ. 2011 Apr;18(4):678-89
pubmed: 21072057
Blood. 1999 Feb 1;93(3):796-803
pubmed: 9920828
Int J Mol Sci. 2020 May 08;21(9):
pubmed: 32397135
J Exp Med. 2001 Jan 15;193(2):247-54
pubmed: 11208865
Leukemia. 2018 Jul;32(7):1493-1499
pubmed: 29445113
Mol Cell. 2001 Sep;8(3):601-11
pubmed: 11583622
Trends Cell Biol. 2013 Mar;23(3):129-34
pubmed: 23117019
Blood. 2004 Jun 1;103(11):4310-6
pubmed: 14976035
Blood. 1999 Jul 1;94(1):87-96
pubmed: 10381501
Cancer Cell. 2014 Oct 13;26(4):509-20
pubmed: 25242043
J Exp Med. 2002 Nov 18;196(10):1347-53
pubmed: 12438425
Cell Rep. 2014 May 8;7(3):661-71
pubmed: 24767991
Br J Haematol. 1995 Sep;91(1):30-6
pubmed: 7577648
PLoS One. 2019 Sep 4;14(9):e0221472
pubmed: 31483850
Cell. 2005 Aug 26;122(4):593-603
pubmed: 16122426
Haematologica. 2020 Jun 05;105(9):2240-2249
pubmed: 33054049
Nature. 2004 Oct 21;431(7011):997-1002
pubmed: 15496926
EMBO J. 2020 Jul 15;39(14):e104410
pubmed: 32511789
Nat Cell Biol. 2006 Dec;8(12):1348-58
pubmed: 17115033
Science. 2000 Dec 1;290(5497):1761-5
pubmed: 11099414
Exp Hematol. 1988 Oct;16(9):758-63
pubmed: 3169158
Nature. 2007 Jan 4;445(7123):102-5
pubmed: 17167422
Dev Cell. 2016 Mar 7;36(5):498-510
pubmed: 26954545
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
Blood. 2013 Apr 18;121(16):3246-53
pubmed: 23422750
Nature. 1999 Sep 30;401(6752):489-93
pubmed: 10519553
Cell Death Differ. 2013 Jul;20(7):869-77
pubmed: 23470523
Oncogene. 2006 Jan 5;25(1):152-9
pubmed: 16186808
Cell Metab. 2013 Sep 3;18(3):325-32
pubmed: 23850316
J Toxicol Sci. 2012 Feb;37(1):23-31
pubmed: 22293409
Cell. 1999 Mar 5;96(5):625-34
pubmed: 10089878
Cell. 1998 Aug 21;94(4):491-501
pubmed: 9727492